Valbiotis SAS (ALVAL) - Total Assets
Based on the latest financial reports, Valbiotis SAS (ALVAL) holds total assets worth €14.39 Million EUR (≈ $16.82 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check ALVAL cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Valbiotis SAS - Total Assets Trend (2015–2025)
This chart illustrates how Valbiotis SAS's total assets have evolved over time, based on quarterly financial data. Explore Valbiotis SAS long-term investment allocation to see how much of total assets are deployed in long-term investments.
Valbiotis SAS - Asset Composition Analysis
Current Asset Composition (December 2025)
Valbiotis SAS's total assets of €14.39 Million consist of 82.8% current assets and 17.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €6.57 Million | 60.3% |
| Accounts Receivable | €255.00K | 1.8% |
| Inventory | €2.46 Million | 17.1% |
| Property, Plant & Equipment | €1.18 Million | 8.2% |
| Intangible Assets | €1.20 Million | 8.4% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Valbiotis SAS's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Valbiotis SAS worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Valbiotis SAS's current assets represent 82.8% of total assets in 2025, an increase from 79.6% in 2015.
- Cash Position: Cash and equivalents constituted 60.3% of total assets in 2025, up from 51.1% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, unchanged from 8.0% in 2015.
- Asset Diversification: The largest asset category is cash and equivalents at 60.3% of total assets.
Valbiotis SAS Competitors by Total Assets
Key competitors of Valbiotis SAS based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Beijing Sanyuan Foods Co Ltd
SHG:600429
|
China | CN¥8.86 Billion |
|
ORKLA ADR/1 NK 625
F:OKL0
|
Germany | €88.70 Billion |
|
Tingyi (Cayman Islands) Holding Corp
F:TYG
|
Germany | €54.94 Billion |
|
The a2 Milk Company Ltd
AU:A2M
|
Australia | AU$1.85 Billion |
|
Zydus Wellness Limited
NSE:ZYDUSWELL
|
India | Rs98.81 Billion |
|
Shandong Bailong Chuangyuan Bio-Tech Co. Ltd.
SHG:605016
|
China | CN¥2.80 Billion |
|
Qianhe Condiment&Food Co Ltd
SHG:603027
|
China | CN¥4.46 Billion |
|
Xinjiang Guannong Fruit & Antler Group Co Ltd
SHG:600251
|
China | CN¥7.31 Billion |
Valbiotis SAS - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.85 | 3.04 | 1.98 |
| Quick Ratio | 2.26 | 2.66 | 1.94 |
| Cash Ratio | 1.57 | 1.43 | 0.08 |
| Working Capital | €7.73 Million | €11.32 Million | €8.58 Million |
Valbiotis SAS - Advanced Valuation Insights
This section examines the relationship between Valbiotis SAS's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.21 |
| Latest Market Cap to Assets Ratio | 1.66 |
| Asset Growth Rate (YoY) | -26.6% |
| Total Assets | €14.39 Million |
| Market Capitalization | $23.90 Million USD |
Valuation Analysis
Above Book Valuation: The market values Valbiotis SAS's assets above their book value (1.66x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Valbiotis SAS's assets decreased by 26.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Valbiotis SAS (2015–2025)
The table below shows the annual total assets of Valbiotis SAS from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €14.39 Million ≈ $16.82 Million |
-26.61% |
| 2024-12-31 | €19.61 Million ≈ $22.92 Million |
-41.14% |
| 2023-12-31 | €33.31 Million ≈ $38.94 Million |
+22.59% |
| 2022-12-31 | €27.17 Million ≈ $31.77 Million |
-4.59% |
| 2021-12-31 | €28.48 Million ≈ $33.29 Million |
+35.60% |
| 2020-12-31 | €21.00 Million ≈ $24.55 Million |
+39.86% |
| 2019-12-31 | €15.02 Million ≈ $17.55 Million |
+26.11% |
| 2018-12-31 | €11.91 Million ≈ $13.92 Million |
-6.34% |
| 2017-12-31 | €12.71 Million ≈ $14.86 Million |
+682.76% |
| 2016-12-31 | €1.62 Million ≈ $1.90 Million |
+40.12% |
| 2015-12-31 | €1.16 Million ≈ $1.35 Million |
-- |
About Valbiotis SAS
Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia. The company offers supplements for immunity and vitality, health and wellbeing, metabolic and cardiovascular health, and beauty and physical comfort. It also develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; T… Read more